Sinovac Biotech Ltd
SVA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001084201
No open-market purchases or sales by Sinovac Biotech Ltd insiders were filed in the last 90 days; 28 institutions reported holding it in 13F filings for Q2 2026, worth $224.9M in total; no superinvestor holds it.
13F holders, Q3 2024
Institutional positions in Sinovac Biotech Ltd as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 9
- −16 vs. Q2 2024
- Shares held
- 14.9M
- −1.46M (−8.9%) vs. Q2 2024
- Total value
- $418.4M
- +$338.8M (+425.8%) vs. Q2 2024
- New holders
- 1
- 1 more added
- Sold out
- 17
- 0 more reduced
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SVA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 28 | $224.9M |
| Q1 2026 | 28 | $40.4M |
| Q4 2025 | 28 | $225.3M |
| Q3 2025 | 27 | $225.0M |
| Q2 2025 | 28 | $375.4M |
| Q1 2025 | 3 | $336.0M |
| Q4 2024 | 4 | $336.0M |
| Q3 2024 | 9 | $418.4M |
| Q2 2024 | 26 | $79.6M |
| Q1 2024 | 26 | $80.7M |
| Q4 2023 | 8 | $342.0M |
| Q3 2023 | 30 | $43.2M |
| Q2 2023 | 29 | $5.58M |
| Q1 2023 | 4 | $957.4M |
| Q4 2022 | 9 | $380.2M |
| Q3 2022 | 30 | $44.0M |
| Q2 2022 | 31 | $44.0M |
| Q1 2022 | 11 | $41.6M |
| Q4 2021 | 29 | $44.9M |
| Q3 2021 | 29 | $44.9M |
| Q2 2021 | 28 | $44.9M |
| Q1 2021 | 29 | $44.8M |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Sinovac Biotech Ltd; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| OrbiMed Advisors LLC | 2,718,735 | $340.0M | 6.22% | 00.0% | Unchanged |
| Vivo Capital, LLC | 11,800,000 | $76.3M | 6.32% | 00.0% | Unchanged |
| Neumann Advisory Hong Kong Ltd | 315,586 | $2.04M | 0.83% | 00.0% | Unchanged |
| Horizon Investments, LLC | 52 | $336 | 0.00% | 00.0% | Unchanged |
| Navellier & Associates Inc | 14,167 | $0 | 0.00% | 00.0% | Unchanged |
| California Public Employees Retirement System | 68,732 | $0 | 0.00% | 00.0% | Unchanged |
| Assetmark, Inc | 21 | $0 | 0.00% | +5+31.3% | Added |
| Financial Gravity Companies, Inc. | 24 | $0 | 0.00% | +24 | New |
| Transamerica Financial Advisors, Inc. | 2 | $0 | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −1,312,520−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −16,430−100.0% | Sold out |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −27,717−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −12,450−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −7,824−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −1,557−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −412−100.0% | Sold out |
| US Bancorp | 0 | $0 | 0.00% | −127−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −5,526−100.0% | Sold out |
| Clearstead Advisors, LLC | 0 | $0 | 0.00% | −500−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −442−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −424−100.0% | Sold out |
| Skandinaviska Enskilda Banken AB (publ) | 0 | $0 | 0.00% | −40,000−100.0% | Sold out |
| Spark Investment Management LLC | 0 | $0 | 0.00% | −29,100−100.0% | Sold out |
| Advisor Group Holdings, Inc. | 0 | $0 | 0.00% | −201−100.0% | Sold out |
| EverSource Wealth Advisors, LLC | 0 | $0 | 0.00% | −4−100.0% | Sold out |
| Atlantic Edge Private Wealth Management, LLC | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| Sofos Investments, Inc. | – | – | – | – | Not filed |